The proteasome is a new, interesting target in cancer drug therapy, and the proteasome inhibitor bortezomib has shown an effect in myeloma patients. It is of interest to efficiently discover and evaluate new proteasome inhibitors. The authors describe the development of an image-based screening assay for the identification of compounds with proteasome-inhibiting activity. The stably transfected human embryo kidney cell line HEK 293 ZsGreen Proteasome Sensor Cell Line expressing the ZsProSensor-1 fusion protein was used for screening and evaluation of proteasome inhibitors. Inhibition of the proteasome leads to accumulation of the green fluorescent protein ZsGreen, which is measured in the ArrayScan ® High Content Screening system, in which cell morphology is studied simultaneously. When screening the LOPAC 1280 substance library, several compounds with effect on the proteasome were found; among the hits were disulfiram and ammonium pyrrolidinedithiocarbamate (PDTC). Cytotoxic analysis of disulfiram and PDTC showed that the compounds induced cytotoxicity in the myeloma cell line RPMI 8226. The average Z′ value for the assay was 0.66. The results indicate that the assay rapidly identifies new proteasome-inhibiting substances, and it will be further used as a tool for image-based screening of other chemically diverse compound libraries. (Journal of Biomolecular
INTRODUCTION
T HE PROTEASOME is a large proteolytic enzymatic complex present in the cytoplasm and the nucleus. It consists of a 20S core catalytic complex with 19S subunits at both ends, 1 and proteins tagged with ubiquitin are transferred to the proteasome for degradation. Cancer cells have been shown to be more susceptible to proteasome inhibition than normal cells are. 2 The end point for most anticancer drugs is cell death, and because traditional cytotoxic drugs often have serious adverse effects, it is important to find new effective, less-toxic anticancer drugs. Recently, the proteasome has emerged as a new interesting target in cancer drug therapy, and the proteasome inhibitor bortezomib has shown promising clinical activity in myeloma patients. 3 Image-based screening has been performed since the late 1990s, and several platforms and assays have been developed in which it is possible to study single cells or subcellular compartments. 4, 5 Multiparametric cellular analyses enhance the drug discovery process by defining toxicity, potency, specificity, and selectivity of pharmacologically active compounds. 6 This leads to a more effective screening process that simultaneously gives information on both the type of cell death and the mechanism of action of the investigated compounds, as well as offering a possibility of identifying false hits.
We have previously described the development of a multiparametric high-content screening (HCS) assay for measurement of apoptosis. 7 In this work, we describe the development of a rapid image-based screening assay for the identification of novel proteasome-inhibiting compounds. We used the stably transfected HEK 293 ZsGreen Proteasome Sensor Cell Line expressing the ZsProSensor-1 fusion protein to screen for proteasome inhibitors in the annotated compound library LOPAC 1280 . The ZsProSensor-1 consists of the green fluorescent protein ZsGreen fused to mouse ornithine decarboxylase (MODC), a protein that is degraded by the 26S proteasome without ubiquitination. 8 Protein inhibitors hinder the degradation of MODC, leading to accumulation of ZsGreen in the cells. The resulting fluorescence was measured in the ArrayScan ® HCS reader.
MATERIALS AND METHODS

Cell culture
The stably transfected HEK 293 ZsGreen Proteasome Sensor Cell Line expressing the ZsProSensor-1 fusion protein 9 (BD Biosciences, San Jose, CA) was used for screening and evaluation of proteasome inhibitors. The cells were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum, 2 mM glutamine, 50 µg/ml streptomycin, and 60 µg/ml penicillin (all from Sigma Aldrich, St. Louis, MO) at 37 °C in humidified air containing 5% CO 2 . The antibiotic G418 was included in the culture medium at a concentration of 0.2 mg/ml to select for stably transfected cells. The cells were adherent and subcultured using trypsinization. The myeloma cell line RPMI 8226 was grown in RPMI 1640 supplemented as above. The HeLa cells were cultured in Minimum Essential Medium Eagle supplemented as above and with 1 mM sodium pyruvate. Growth and morphology of the cell lines were monitored on a weekly basis.
Compound library
Compounds used for screening were part of the LOPAC 1280 library (Sigma Aldrich). The library is a collection of 1266 pharmacologically active compounds from 56 pharmacological classes 10 consisting of marketed drugs, failed development candidates, and gold standards that have well-characterized activities. The compounds were dissolved in DMSO, further diluted with phosphate-buffered saline (PBS), and transferred to 384deep-well microplates (Nunc, Roskilde, Denmark) using the Biomek 2000 pipetting station (Beckman Coulter Inc., Fullerton, CA). The plates were stored at -70° C until further use. The clinically used proteasome inhibitor bortezomib was used as positive control and was provided by Millennium Pharmaceuticals (Cambridge, MA). The experimental proteasome inhibitors MG262 (Calbiochem, San Diego, CA) and lactacystin (Sigma Aldrich) were used as positive controls when retesting the hits.
Image-based screening assay for proteasome activity
HEK 293 ZsGreen cells were seeded at a density of 2750 cells per well using the pipetting robot Precision 2000 (BioTek Instruments Inc., Winooski, VT) in 4 black, 384-well microplates (Falcon). The cells were allowed to adhere for 1 h and were then incubated at 37 °C for another 9 h. Thereafter, 5 µl of drug per well were added using the Biomek 2000 pipetting station (Beckman Coulter), giving a screening concentration of 10 µM. Two columns without drugs served as controls, and 1 column with medium only served as blank. A total of 10 µM bortezomib was added as a positive control in 1 column. The plates were incubated at 37 °C for 12 h. The medium was then removed using ELx405™ (BioTek Instruments Inc.), the cells were fixed with 40 µl of 3.7% paraformaldehyde, and 10 µM Hoechst 33342 were added (Multidrop 384; Titertek, Huntsville, AL). The plates were incubated for 15 min, washed with PBS, sealed, and kept at 4 °C in darkness until image analysis. The final DMSO concentration was a maximum of 1%. When retesting the hits, the active compounds were manually picked from the library and were first tested on HeLa cells using the same procedures and settings as in the screening. Compounds with high fluorescence were considered autofluorescent. The remaining compounds, as well as MG262 and lactacystin, were retested in the HEK 293 ZsGreen cells in flat-bottomed 96-well plates and left to adhere for 2 h. The active compounds were added to the cells for 12 h. Then the cells were fixed and washed, and the plates were analyzed using the same procedures and settings as in the screening.
Image acquisition and cytometric analysis
Plates with stained and fixed cells were analyzed using the ArrayScan ® HCS reader software (Cellomics Inc., Pittsburgh, PA). This system is a computerized automated fluorescence imaging microscope that automatically identifies stained cells and reports the intensity and distribution of fluorescence in individual cells. Images were acquired for each fluorescence channel, Hoechst 33342 and FITC, using XF100 filters with a 5× objective. To quantify the degree of 26S proteasome inhibition, the intensity of the fluorescence of each well was measured. In each well, up to 700 cells were analyzed. Automatic focusing was performed in the nuclear channel to ensure focusing regardless of staining intensities in the other channels. Images and data regarding intensity and texture of the fluorescence within each cell, as well as the average fluorescence of the cell population within the well, were stored in a Microsoft SQL database for easy retrieval. The time required to read 1 plate was 22 min.
Cytotoxicity assay
The fluorometric microculture cytotoxicity assay (FMCA) described in detail previously 10, 11 was performed to measure cytotoxic activity of the compounds. Briefly, this assay measures hydrolysis of fluorescein diacetate (FDA) to fluorescein by cells with intact plasma membranes. For experiments, cell suspension was added to drug-prepared 384-well microplates. The plates were incubated at 37 °C for 72 h and then transferred to an integrated SAGIAN™ Core System for high-throughput screening (HTS; Beckman Coulter Inc.). Medium and drugs were aspirated, the cells were washed twice with PBS, 50 µl of physiological buffer and 1 µl of 0.5 mg/ml FDA were added, and after 50 to 70 min of incubation, the fluorescence, which is proportional to the number of living cells, was measured at 485/520 nm in the FLUOstar Optima (BMG Labtech Gmbh, Offenburg, Germany). Cell survival is presented as the Survival Index (SI), defined as fluorescence in test wells in percentage of control wells, with blank values subtracted.
Activity assay for 20S proteasome
The enzymatic activity of the 20S proteasome was determined using the 20S proteasome assay kit (BIOMOL International LP, Plymouth Meeting, PA) according to the instructions of the manufacturer. Briefly, 20S activity was measured by adding test substances or known inhibitors to human erythrocyte 20S enzyme in an assay buffer of 25 mM HEPES (pH 7.5), 0.5 mM EDTA, 0.05% NP-40, and 0.03% SDS. After a 10-min incubation to allow enzyme and substrate interaction, the fluorogenic proteasome substrate SUC-LLVY-AMC was added. The increase in fluorescence was measured every 3rd minute during 1 h at 37 °C in the FLUOStar Optima using excitation and emission wavelengths of 340 and 450 nm, respectively. Monitoring the increase in fluorescence over time allowed quantification of the enzymatic activity.
Statistics
Statistical analysis was performed using GraphPadPrism (GraphPad Software, Inc., San Diego, CA). Data were processed using nonlinear regression and a standard sigmoidal doseresponse model to obtain logIC 50 values (inhibitory concentration 50%). Dose-response data are presented as means ± standard errors from 3 independent experiments, with duplicate wells for each concentration and compound. To evaluate the usefulness of the assay in a screening setting, the Z′ value was calculated according to Zhang and others 12 
RESULTS
Method development and hit rate
In the assay described in this article, we used the HEK 293 ZsGreen Proteasome Sensor Cell Line expressing the ZsProSensor-1 fusion protein to screen for proteasome inhibitors. We performed the screen in the ArrayScan ® HCS reader and further tested the hit compounds in a 20S enzymatic assay. Finally, we tested the compounds for cytotoxicity in a myeloma cell line. A flow chart of the assay procedure is displayed in Figure 1 . The fluorescent signal in each well was measured in the ArrayScan ® , and a compound was considered a hit if the signal in the well was above 3 standard deviations (SD) of the average negative control signal, which was 11.1. The 3 SD cutoff was 17.1. The screening resulted in 14 compounds with proteasome-inhibiting activity (Fig. 2) . A histogram of the screening results is presented in Figure 3 , in which the hit compounds are indicated with arrows. After the initial screen, the images of the hit compounds were inspected manually to determine if the fluorescence was present in the cells. In this experiment, the plates were incubated for 12 h. This time point was too short to detect large changes in texture of the nuclei or the proteasome staining pattern. In some wells, there was debris present, which contributed to the fluorescence, and some compounds were autofluorescent. Both these events were considered as artifacts. After exclusion of artifacts, 7 compounds from LOPAC remained, and retesting was performed. In the retesting, the hit compounds were cherry-picked, and the experimental proteasome inhibitors lactacystin and MG262 were added. Eight compounds were confirmed hits after retesting, which yielded 57% true hits and a total hit rate of 0.63%. Figure 4 displays images of the positive control bortezomib and 2 of the hit compounds, disulfiram and ammonium pyrrolidinedithiocarbamate (PDTC). The image algorithm works by identifying the nuclear staining in channel 1. On the basis of the nuclear staining, the area of interest in the 2 nd channel, FITC, was identified by expanding the area by 1 pixel. This expansion was necessary to cover parts of the cytoplasmic regions of the cells.
Feasibility of screening for proteasome-inhibiting activity
The dynamic range of the assay signal and the variability of the signal in negative and positive controls are important for the ability to identify hits in a screening assay. For Z′ value calculations, HEK 293 ZsGreen cells were exposed to PBS or the positive control bortezomib at 10 µM for 12 h. Analysis of fluorescence intensity in 700 cells per well using 5× objective was performed. For this purpose, 3 plates were analyzed, and the average reading time of 1 plate was 22 minutes. The average Z′ value was calculated to 0.66. A plot of individual well signals from both negative and positive control (176 samples each) is shown in Figure 5 . This assay is suitable for screening because it is quick and relatively cheap since there are no additional reagents used. The only components of the assay are HEK 293 ZsGreen Proteasome Sensor Cell Line, the screening library, microplates, cell culture material, paraformaldehyde, and Hoechst 33342.
20S proteasome enzymatic activity
To examine if the hit compounds were acting on the largest subunit of the proteasome, the 20S proteasome assay kit was used. Studies using purified SDS-activated 20S proteasome indicated inhibitory activity of the proteasome-inhibiting compounds MG262 and lactacystin but not for NSC 95397, disulfiram, PDTC, A-77636, 7-chloro-4-hydroxy-2-phenyl-1,8-naphthyridine (7-CHPN), or 4-amino-1,8-naphthalimide (4-AN), which is shown in Figure 6 .
Cytotoxic activity of the hit compounds
Of the 8 hit compounds, 6 were cytotoxic in the myeloma cell line RPMI 8226, namely, NSC 95397, disulfiram, PDTC, A-77636, MG262, and lactacystin. Dose-response curves of all compounds including the 2 that were not cytotoxic are presented in Figure 7 , and IC 50 values of the cytotoxic compounds are shown in Figure 2 . Data are presented as means ± standard errors from 3 independent experiments performed with the drugs in duplicate for each concentration.
DISCUSSION
In this work, we describe the development of a rapid screening assay for evaluating proteasome activity. The proteasome has emerged as a new target in cancer therapy, in which the proteasome inhibitor bortezomib is approved for treatment of multiple myeloma. The ZsProSensor-1 fusion protein, which is transfected into the HEK 293 ZsGreen Proteasome Sensor Cell Line, has been used previously to study proteasome function. 13 In this work, we used the HEK 293 ZsGreen Proteasome Sensor Cell Line in an image-based screen with the aim of identifying proteasome inhibitors in the annotated compound library LOPAC 1280 . Image-based screening has been performed since the late 1990s, and HCS, which studies several parameters simultaneously, was first described by Giuliano and others in 1997 14 and has since then been shown to be of use in many areas of research such as cancer, 15 neurite outgrowth, 16 and inflammation. 17 In this assay, 14 of 1266 compounds were initially detected as proteasome inhibitors. After exclusion of artifacts and retesting, 8 of these were active. This gives a true hit rate of 57%. The LOPAC 1280 library was also tested for cytotoxicity in the FMCA. Because the approved proteasome inhibitor bortezomib is used in 3 rd -line treatment of multiple myeloma, the cytotoxicity was tested in the myeloma cell line RPMI 8226. Of the 8 hit compounds, 6 were cytotoxic, namely, the Cdc25 phosphatase inhibitor NSC 95397, 18 the antialcoholism drug disulfiram, the disulfiram-metabolite PDTC, the dopamine-agonist A-77636, and the proteasome inhibitors MG262 and lactacystin, which had been added to the library as positive controls. Of the other compounds, disulfiram 19 and PDTC have been described as proteasome inhibitors before but in combination with copper. 20, 21 The dose-response curve for disulfiram was atypical in that it is biphasic. The IC 50 value for disulfiram was 0.12 µM, but at higher concentrations of about 10 µM, the SI increased. This phenomenon has been previously described for dithiocarbamates, 22 but the underlying mechanisms are not fully understood. The biphasic pattern was not present for the disulfiram metabolite PDTC at the investigated concentrations.
To investigate on what part of the proteasome the active compounds were acting, an assay measuring the activity of the 20S enzyme was performed. The 20S subunit has chymotrypsinactivity, 23 used to study the inhibition of chymotrypsin. 24, 25 Only lactacystin and MG262 were active in the 20S assay, indicating that the other hits act on a different part of the proteasome or other signaling pathways affecting its activity. This has previously been described for disulfiram and PDTC. 19 NSC 95397 has previously been described as a Cdc25 phosphatase inhibitor. 18 Cdc25 phosphatases are involved in regulation of the cell cycle by activating Cdk/cyclin complexes. 26 The Cdc25s are degraded by the proteasome, and whether the observed effect of NSC 95397 depends on the Cdc25 inhibition or a direct proteasome inhibition remains unknown. The proteasome consists of a 20S core catalytic complex and a 19S regulatory complex with 19S subunits that bind to both ends of the 20S proteasome to form the 26S proteasome. 2 The 19S seems to consist of a base and a lid, in which the base is able to degrade peptides and nonubiquitylated proteins and the lid to degrade ubiquitylated proteins. 27 There is also the 11S regulator, which associates with the 20S proteasome and might be involved in promoting the production of antigenic peptides. 28 Thus, the 26 proteasome consists of several subunits with different activities, which might be possible drug targets. A-77636 is a selective dopamine agonist acting on the D1receptor. 29 A-77636 has not previously been involved in proteasome inhibition; however, a recent study described that oxidation products of dopamine can inhibit the proteasome. 30 It is not known on what part of the proteasome A-77636 and the oxidation products are acting, and the inhibition might be exerted by different mechanisms. However, it is interesting because the proteasome has been shown to be of importance in parkinsonism. 31 There are no previous reports of any cytotoxic activity of A-77636, but we have screened the LOPAC library on a number of cell lines in our laboratory, and the dopamine D1-agonist dihydrexidine was cytotoxic in RPMI 8226 and several other tumor cell lines with an IC 50 of 2 µM in RPMI 8226 (unpublished data), which indicates that dopamine agonists can be cytotoxic in vitro.
The identification of the antialcoholism drug disulfiram as a proteasome inhibitor was unexpected. Disulfiram has earlier been shown, in a complex with copper, to cause apoptosis in human melanoma cells 32 and in colon cancer by inhibiting NF-κB nuclear translocation. 33 We recently showed, however, that disulfiram was acting by inhibiting proteasome activity and NF-κB translocation to the nucleus. 19 The cell characteristics of disulfiram have also recently been investigated in our laboratory, where disulfiram was shown to cause apoptosis, and when tested on patient samples from a variety of cancer diagnoses, leukemias and ovarian carcinoma were the most sensitive. 34 Since the detection of the proteasome as a new target in cancer therapy, several approaches have been used to identify compounds acting as proteasome inhibitors. There are methods for screening peptide-based covalent inhibitors of the proteasome, as described in a recent review with a focus on finding specific inhibitors, designed for having proteasome-inhibiting activity. 35 Along with screening to identify new drugs, novel proteasome inhibitors have also been synthesized, often with a peptide as a core. 36 Our focus was to develop a simple, cost-effective, and reliable assay for HTS application. We therefore screened a commercially available annotated substance library to find compounds with other mechanisms of action that might also have proteasome-inhibiting activity. The present assay is technically simple and cost-effective, requiring no expensive assay reagents because we measured the fluorescence yielded from the transfected HEK 293 ZsGreen Proteasome Sensor Cell Line. It is possible to perform the assay in a 96-well or 384-well format. The Z′ value is a statistical parameter for evaluating assay quality, 12 and the average Z′ value for this assay was calculated to 0.66, indicating a high dynamic range with low variability. Thus, the results indicate that this image-based screening assay is a rapid and reliable method for identifying compounds with proteasome-inhibiting activity. This screening assay could have been performed using a fluorescence reader; however, the described image-based assay offers the opportunity to simultaneously measure multiple targets within the cells to correlate, for example, nuclear fragmentation, NF-κB translocation, and proteasome inhibition on a single-cell level. Development of such extended versions of this assay is ongoing.
CONCLUSIONS
In this article, we have described a new image-based screening assay for the identification of proteasome inhibitors. The results indicate that the assay quickly identifies new proteasomeinhibiting substances in a compound library consisting of wellknown substances, and it will be further used as a tool for image-based screening of other compound libraries.
